Not available
Quote | AstraZeneca PLC (NYSE:AZN)
Last: | $55.51 |
---|---|
Change Percent: | 2.47% |
Open: | $54.2 |
Close: | $55.51 |
High: | $55.84 |
Low: | $54.02 |
Volume: | 4,954,076 |
Last Trade Date Time: | 09/25/2020 04:55:24 pm |
News | AstraZeneca PLC (NYSE:AZN)
2024-07-02 11:20:47 ET Summary This article will outline nine steps I use to identify the most promising pharmaceutical companies and avoid investment pitfalls. In addition, each of the nine steps will provide examples of various factors and how they influence the assessment of th...
2024-07-02 09:17:30 ET More on Eli Lilly 5 Reasons Eli Lilly Just Keeps Rising Eli Lilly: Throwing Its Weight Around - But, For How Long? (Technical Analysis) Eli Lilly: The Party Is Probably Nearing The End Lilly in deal with Radionetics Oncology on radiopha...
Message Board Posts | AstraZeneca PLC (NYSE:AZN)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $AZN News Article - AstraZeneca PLC (NASDAQ: AZN) Records 52-Week High Friday Morning | whytestocks | investorshangout | 04/21/2023 7:30:49 PM |
whytestocks: $AZN News Article - AstraZeneca PLC (NASDAQ: AZN) Records 52-Week High Tuesday Morning | whytestocks | investorshangout | 04/18/2023 7:20:48 PM |
https://twitter.com/Prof_Oak_/status/1646929438594957312 | jondoeuk | investorshub | 04/14/2023 6:02:56 PM |
whytestocks: $AZN News Article - Fusion Pharmaceuticals Announces IND Clearance for FPI-2068, a Join | whytestocks | investorshangout | 04/12/2023 8:25:49 PM |
whytestocks: $AZN News Article - Astrazeneca Plc (NASDAQ: AZN) Highlighted for Surprising Price Acti | whytestocks | investorshangout | 04/05/2023 6:05:46 PM |
News, Short Squeeze, Breakout and More Instantly...
2024-07-02 08:30:07 ET Jefferies analyst issues HOLD recommendation for AZN on July 2, 2024 06:20AM ET. The previous analyst recommendation was Hold. AZN was trading at $77.94 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
2024-06-29 22:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
First immunotherapy regimen before and after surgery to extend survival in bladder cancer Positive high-level results from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab) in combination with chemotherapy demonstrated a statistically sign...